Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pfs230 is a large, cysteine-rich surface protein expressed by the malaria parasite *Plasmodium falciparum* during its sexual stages. It is a leading target for malaria transmission-blocking vaccines (TBVs) due to its essential role in parasite development and transmission from humans to mosquitoes. It is required for male/female gamete fusion, essential for male gamete exflagellation, and involved in interaction with host erythrocytes; parasites lacking Pfs230 cannot bind red blood cells or develop into oocysts within mosquitoes, thus blocking transmission. Antibodies against specific regions—especially domain 1—can block parasite transmission.
Antibody-mediated blocking of gamete fusion and parasite development in mosquitoes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gametocyte Surface Protein PFS230 (Pfs230).